TrialPath

Find a study

Match me to a study

189 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders — Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, PhoenixThis Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment — Cahaba Dermatology & Skin Health Center- Site Number : 8400006, BirminghamA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamComparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Children's of Alabama (MRD-HCT), BirminghamReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Long-term Follow-up Study in Patients Who Received BEAM-101 — University of Alabama at Birmingham, BirminghamThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterPeer Support for Adolescents and Emerging Adults With Sickle Cell Pain — University of South Alabama Medical Center, MobileA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandRecruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease — University of Alabama, Birmingham (UAB), BirminghamA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamAchieving Understanding of the Natural History of Sickle Cell Trait (AUNT) — University of Alabama, BirminghamRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaSickle Cell Clinical Research and Intervention Program — Children's Hospital of Illinois at OSF-Saint Francis Medical Center, PeoriaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesCooperative Assessment of Late Effects for SCD Curative Therapies — Children's National Medical Center, Washington D.C.Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesA Socio-ecological Approach for Improving Self-management in Adolescents With SCD — Nemours Children's Health, WilmingtonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraDelivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease — University of Illinois at Chicago, ChicagoReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenEvaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares — U.S. Dermatology Partners, PhoenixA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkIntegrative Training Program for Pediatric Sickle Cell Pain — Connecticut Children's Medical Center, HartfordApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness — Lurie Children's Hospital, ChicagoSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaMULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease — UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, ClevelandA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoStudy of the Role of Genetic Modifiers in Hemoglobinopathies — Boston Children's Hospital, BostonEffect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia — Magee Women's Hospital, PittsburghVerifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease — Cincinnati Children's Hospital Medical Center, CincinnatiSickle Cell Kidney Biorepository — Parkland Memorial Hospital, DallasArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease — Methodist Comprehensive Sickle Cell Center, MemphisSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghA Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up — National Institutes of Health Clinical Center, BethesdaStudy to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaSickle Cell Improvement: Enhancing Care in the Emergency Department — Children's Wisconsin, MilwaukeePeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisHydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation — Cincinnati Children's Hospital Medical Center, CincinnatiSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceSickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders — St. Jude Children's Research Hospital, MemphisVirtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises — University of Maryland Medical Systems, BaltimoreSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX) — St. Jude Children's Research Hospital, MemphisDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaLet's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy — Washington University School of Medicine, St LouisMindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease — University of Illinois Chicago, ChicagoCognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamFLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases — xCures, Los AltosStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaDietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaIntegrative Medicine in Pain Management in Sickle Cell Disease, 2.0 — Indiana University School of Medicine, IndianapolisCollection of Human Biospecimens for Basic and Clinical Research Into Globin Variants — National Institutes of Health Clinical Center, BethesdaCutaneous Hydration Assessment in SCD — UPMC Sickle Cell Clinic, PittsburghPredictors of Pain in Sickle Cell Disease — Duke University Medical Center, DurhamSickleFit Exercise and Nutrition Study — Duke University, DurhamPromoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease — Boston Children's Hospital, BostonSickle Cell Disease Biofluid Chip Technology (SCD BioChip) — University Hospitals Case Medical Center, ClevelandEmpowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA) — Nemours Children's Hospital, Delaware, WilmingtonAdvancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease — Children's National Hospital, Washington D.C.AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, ValhallaCerebral Oxygen Metabolism in Children — Washington University of St. Louis, St LouisMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoWriting Relaxing Beats in Adolescents Who Have Sickle Cell Disease — Mayo Clinic Division of Nursing, RochesterTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoSchool Readiness Intervention for Preschool Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaA Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease — Boston Children's Hospital, BostonHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease — Children's Hospital of Atlanta: Eagelston, AtlantaExercise in Child Health — University of California, Irvine, IrvineMetabolic and Hemodynamic Reserve in Pediatric SCA — Washington University in St. Louis, St LouisStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaGenotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaEarly Life Exposures Among Children With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamSMYLS Multi-site Trial — Medical University of South Carolina, CharlestonStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoSickle Cell, Pain and Mediterranean Diet — University of Illinois Chicago, ChicagoInvestigation of the Genetics of Hematologic Diseases — St. Jude Children's Research Hospital, MemphisA Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease — University of Florida, GainesvilleCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanAn mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoStress Management and Mindfulness Intervention for Patients With Sickle Cell Disease — University of Pennsylvania, PhiladelphiaT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghA Real-World Registry of Chronic Wounds and Ulcers — US Wound Registry, The WoodlandsCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain — Mount Sinai Hospital, New YorkBlood Sampling for Research Related to Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaUltrasound Acute Chest Syndrome Sickle Cell Disease — Indiana University, IndianapolisTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoATHNdataset Registry — American Thrombosis and Hemostasis Network, HickoryEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisVirtual Reality As Adjunct Therapy for Vaso-Occlusive Pain — Children's Hospital of New Orleans, New OrleansRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaFeasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease — Children's National Hospital, Washington D.C.Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies — National Institutes of Health Clinical Center, BethesdaA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoBone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait — UConn Health, FarmingtonIntravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease — Children's National Hospital, Washington D.C.Gene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisFunctional Ovarian Reserve in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonA Feasiblity Study of Green Activity Program for People Living With Memory Challenges — Indiana University Bloomington, BloomingtonEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East Windsor

Showing the 150 nearest — narrow your filters for fewer, closer studies.